Compugen Earnings Call: Cash Windfall, Trials and Risks

Compugen ((CGEN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Compugen’s latest earnings call struck an upbeat tone, as management highlighted a transformed balance sheet, a swing to profitability, and visible clinical momentum across key oncology programs. Executives also acknowledged that the good news is tempered by lumpy, deal‑driven revenues and partner‑dependent milestones, but the overall outlook remained clearly positive.

Extended Cash Runway and Strong Year‑End Cash Balance

Compugen underscored a major improvement in financial flexibility after a non‑dilutive deal with AstraZeneca extended its cash runway into 2029, even assuming no additional inflows. The company ended 2025 with about $145.6 million in cash, cash equivalents, short‑term deposits and marketable securities, including the $65 million AstraZeneca upfront.

Substantial Revenue Increase Driven by Partner Upfronts

Revenue surged in the fourth quarter of 2025 to roughly $67.3 million from $1.5 million a year earlier, while full‑year revenue jumped to about $72.8 million from $27.9 million. Management stressed that this growth was largely driven by the $65 million AstraZeneca upfront and payments from the Gilead collaboration, rather than recurring product sales.

Swing to Profitability

The company posted a Q4 2025 net profit of about $56.8 million, or $0.60 per share, reversing a $6.1 million loss in the prior‑year quarter. For the full year, Compugen reported net income of roughly $35.3 million, or $0.38 per share, compared with a $14.2 million loss in 2024, a shift mainly tied to the large non‑recurring partner payments.

Clinical Advancement of COM701 Ovarian Program

On the clinical front, Compugen launched dosing in the MAIA adaptive randomized maintenance trial of COM701 in platinum‑sensitive ovarian cancer, expanding to 28 sites across the U.S., Israel and France. Pooled Phase I data in platinum‑resistant disease, presented at ESMO, showed COM701 was well tolerated with durable responses in heavily pretreated patients, particularly those without liver metastases.

Progress on GS‑0321 and Partner Funding

GS‑0321, an anti–IL‑18BP antibody partnered with Gilead, has moved into a Phase I dose‑escalation and expansion study, with the first patient dosed in January 2025 and early visibility via a SITC presentation. Financially, Gilead has already paid €60 million upfront plus $30 million on IND clearance, and Compugen remains eligible for up to $758 million in future milestones alongside tiered royalties.

Partnership Validation and Upside from Rilvegostomig

Management highlighted its deepening relationship with AstraZeneca as a key value driver, citing the monetization transaction and AstraZeneca’s broad late‑stage program for rilvegostomig with around 10 to 11 Phase III studies underway. Compugen has kept most of its royalty interests and can earn mid‑single‑digit tiered royalties, while AstraZeneca has previously pointed to potential peak annual sales above $5 billion for the asset.

Controlled Operating Expenses

Operating discipline remained a theme as R&D expenses slipped to about $5.5 million in Q4 and $22.8 million for 2025, down high‑single digits from 2024 as earlier trials wound down. G&A costs also edged lower to roughly $2.1 million in the quarter and $8.9 million for the year, with management reallocating spend toward MAIA and early‑stage programs while keeping overall costs in check.

Revenue Largely Lumpy and Deal‑Driven

Executives cautioned that 2025’s standout revenue and profit are heavily influenced by one‑time partner payments, making results inherently volatile. With no commercial product yet, Compugen’s top line remains concentrated in milestone and upfront payments, leaving future revenue timing tied to partner progress rather than predictable operations.

Timing Delays in COM701 Interim Readout

The company pushed back the planned interim analysis for the MAIA COM701 ovarian trial from 2026 to the first quarter of 2027 due to slower opening of major U.S. academic sites and a slower‑than‑expected accumulation of events. Management noted that 28 sites are now active and reaffirmed Q1 2027 as the target, while acknowledging that enrollment dynamics remain a key execution risk.

Dependence on Partners for Development and Data Disclosure

Compugen emphasized that progress and communications for key assets are largely in partner hands, with AstraZeneca steering decisions and data flow for rilvegostomig and Gilead controlling GS‑0321 disclosures. This structure supports funding and scale but limits the company’s ability to dictate milestone timing or the cadence of clinical readouts to the market.

Clinical and Competitive Risk in the TIGIT Field

Management addressed broader uncertainty in the TIGIT checkpoint space, noting past setbacks in the field while arguing that its approach, including combination strategies and formats, is differentiated. Still, success hinges on clinical outcomes from AstraZeneca’s rilvegostomig program and future COM902 development, leaving investors exposed to scientific and competitive risk.

Milestones and Future Payments Are Contingent

The call highlighted a sizable pool of potential milestones, including up to $195 million remaining from the AstraZeneca collaboration, with a $25 million payment tied to regulatory progress, plus as much as $758 million from Gilead. However, management was clear that these sums depend on successful clinical and regulatory events, making both timing and ultimate realization uncertain.

Forward‑Looking Guidance and Strategic Outlook

Looking ahead, Compugen plans to leverage its roughly $145.6 million cash position to fund operations into 2029 while advancing COM701, GS‑0321 and its early pipeline. Near‑term value drivers include the COM701 MAIA interim analysis expected in Q1 2027 and potential AstraZeneca and Gilead milestones, with the two partnerships together representing up to about $1 billion in possible future payments plus royalties.

Compugen’s earnings call painted the picture of a small biotech that has bought itself time and flexibility through savvy partnering and tight cost control, turning a prior loss into solid profits for 2025. For investors, the story now rests on execution in the clinic and on partners’ success in converting promising late‑stage programs into durable cash flows over the next several years.